Patents by Inventor Roberto A. Maldonado

Roberto A. Maldonado has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE IMMUNE RESPONSES TO THERAPEUTIC PROTEINS
    Publication number: 20160220501
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins.
    Type: Application
    Filed: February 3, 2015
    Publication date: August 4, 2016
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
    Patent number: 9333234
    Abstract: The present invention relates to a combination which comprises (a) a somatostatin analog and (b) a 11beta-hydroxylase inhibitor; each in free form or in the form of a pharmaceutical acceptable salt thereof; the use of such a combination for the preparation of a medicament for the treatment of diseases associated with increased stress hormone levels; a commercial package or product comprising such a combination; and to a method of treatment of a warm-blooded animal, especially a human.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: May 10, 2016
    Assignee: Novartis AG
    Inventors: Germo Hans Gericke, Herbert Anton Schmid, Mario Roberto Maldonado Lutomirsky, Li Li
  • Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
    Patent number: 9295718
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: March 29, 2016
    Assignee: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • Tolerogenic synthetic nanocarriers to reduce cytotoxic T lymphocyte responses
    Patent number: 9289477
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class I-restricted and/or MHC Class II-restricted epitopes associated with undesired CD8+ T cell responses and immunosuppressants that provide tolerogenic immune responses against antigens that comprise the epitopes.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: March 22, 2016
    Assignee: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • Tolerogenic synthetic nanocarriers for allergy therapy
    Patent number: 9289476
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: March 22, 2016
    Assignee: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • Tolerogenic synthetic nanocarriers
    Patent number: 9265815
    Abstract: This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: February 23, 2016
    Assignee: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Grayson B. Lipford, Christopher J. Roy, Roberto A. Maldonado
  • TOLEROGENIC SYNTHETIC NANOCARRIERS FOR GENERATING CD8+ REGULATORY T CELLS
    Publication number: 20160030555
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.
    Type: Application
    Filed: July 27, 2015
    Publication date: February 4, 2016
    Applicant: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY
    Publication number: 20160030554
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.
    Type: Application
    Filed: July 27, 2015
    Publication date: February 4, 2016
    Applicant: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES
    Publication number: 20160022650
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class I-restricted and/or MHC Class II-restricted epitopes associated with undesired CD8+ T cell responses and immunosuppressants that provide tolerogenic immune responses against antigens that comprise the epitopes.
    Type: Application
    Filed: July 27, 2015
    Publication date: January 28, 2016
    Applicant: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE IMMUNE RESPONSES TO THERAPEUTIC PROTEINS
    Publication number: 20150335762
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins.
    Type: Application
    Filed: July 27, 2015
    Publication date: November 26, 2015
    Applicant: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • TOLEROGENIC SYNTHETIC NANOCARRIERS
    Publication number: 20150328333
    Abstract: This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses.
    Type: Application
    Filed: July 27, 2015
    Publication date: November 19, 2015
    Applicant: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Grayson B. Lipford, Christopher J. Roy, Roberto A. Maldonado
  • TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE ANTIBODY RESPONSES
    Publication number: 20150320728
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class II-restricted epitopes and immunosuppressants that provide tolerogenic immune responses, such as a reduction in CD4+T cell help specific to an antigen.
    Type: Application
    Filed: July 27, 2015
    Publication date: November 12, 2015
    Applicant: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • CONTROLLED RELEASE OF IMMUNOSUPPRESSANTS FROM SYNTHETIC NANOCARRIERS
    Publication number: 20150320856
    Abstract: Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.
    Type: Application
    Filed: July 17, 2015
    Publication date: November 12, 2015
    Applicant: Selecta Biosciences, Inc.
    Inventors: David H. Altreuter, Aaron P. Griset, Roberto A. Maldonado
  • TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ANTIGEN-SPECIFIC DELETION OF T EFFECTOR CELLS
    Publication number: 20150320884
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion).
    Type: Application
    Filed: July 27, 2015
    Publication date: November 12, 2015
    Applicant: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • TOLEROGENIC SYNTHETIC NANOCARRIERS FOR INDUCING REGULATORY B CELLS
    Publication number: 20150320870
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising B cell and/or MHC Class II-restricted epitopes and immunosuppressants in order to generate tolerogenic immune responses, such as the generation of antigen-specific regulatory B cells.
    Type: Application
    Filed: July 27, 2015
    Publication date: November 12, 2015
    Applicant: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado
  • COMBINATION OF SOMATOSTATIN-ANALOGS WITH 11BETA-HYDROXYLASE INHIBITORS
    Publication number: 20150087588
    Abstract: The present invention relates to a combination which comprises (a) a somatostatin analogue and (b) a 11beta-hydroxylase inhibitor; each in free form or in the form of a pharmaceutical acceptable salt thereof; the use of such a combination for the preparation of a medicament for the treatment of diseases associated with increased stress hormone levels; a commercial package or product comprising such a combination; and to a method of treatment of a warm-blooded animal, especially a human.
    Type: Application
    Filed: April 10, 2013
    Publication date: March 26, 2015
    Applicant: Novatis AG
    Inventors: Germo Hans Gericke, Herbert Anton Schmid, Mario Roberto Maldonado Lutomirsky, Li Li
  • REPEATED ADMINISTRATION OF NON-IMMUNOSUPPRESSIVE ANTIGEN SPECIFIC IMMUNOTHERAPEUTICS
    Publication number: 20140356361
    Abstract: This invention relates to repeated administration of antigen-specific immunotherapeutics using protocols, or elements thereof, that do not induce immunosuppression. In some embodiments, the protocol has been previously shown not to induce immunosuppression in a subject.
    Type: Application
    Filed: June 4, 2014
    Publication date: December 4, 2014
    Applicant: Selecta Biosciences, Inc.
    Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
  • METHODS AND COMPOSITIONS FOR ENHANCING CD4+ REGULATORY T CELLS
    Publication number: 20140335186
    Abstract: Disclosed are methods and related compositions for administering immunosuppressants and therapeutic macromolecules for enhancing CD4+ regulatory T cells.
    Type: Application
    Filed: May 2, 2014
    Publication date: November 13, 2014
    Applicant: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Roberto A. Maldonado
  • LOCAL, CONCOMITANT ADMINISTRATION OF TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE TYPE I AND TYPE IV HYPERSENSITIVITY
    Publication number: 20140328922
    Abstract: Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity.
    Type: Application
    Filed: May 2, 2014
    Publication date: November 6, 2014
    Applicant: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado
  • DOSING COMBINATIONS FOR REDUCING UNDESIRED HUMORAL IMMUNE RESPONSES
    Publication number: 20140328923
    Abstract: Disclosed are dosings of therapeutic macromolecules and immunosuppressants, in some embodiments attached to synthetic nanocarriers, in combination with dosings of therapeutic macromolecules without synthetic nanocarriers, and related methods that provide reduced humoral immune responses.
    Type: Application
    Filed: May 2, 2014
    Publication date: November 6, 2014
    Applicant: Selecta Biosciences, Inc.
    Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto